Pharmacoeconomics of Antihypertensive Drug Treatment: An Analysis of How Long Patients Remain on Various Antihypertensive Therapies
Open Access
- 1 February 2004
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 6 (2) , 76-82
Abstract
The objective of the research was to perform a clinical practice‐based analysis of how long patients remain on various antihypertensive drugs. An administrative database listing of patient baseline characteristics, drug prescriptions, and hospital admissions was used. All new users of antihypertensive drugs, ≥20 years of age, receiving a first prescription for diuretics, β blockers, calcium channel blockers, angiotensin‐converting enzyme inhibitors, or angiotensin II receptor antagonists between January 1, 2000, and December 31, 2000, were included and observed for 365 days. Persistence was defined as a duration of therapy >273 days. A total of 14,062 patients were included in the study, 39.7% of whom remained on treatment (persistent patients). Persistent patients were more likely to be older, taking other drugs for concurrent disorders, hospitalized for cardiovascular diseases, and initially prescribed angiotensin II receptor antagonists. Persistent patients accounted for 80.6% of the overall cost for antihypertensive drugs. Factors associated with drug cost were age, pattern of persistence, number of prescribed classes, and specific medication at enrollment. Measuring persistence with treatment is needed to evaluate the appropriateness and the cost‐effectiveness of drug use.Keywords
This publication has 29 references indexed in Scilit:
- Long-term persistence with antihypertensive drugs in new patientsJournal of Human Hypertension, 2002
- The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureArchives of internal medicine (1960), 1997
- Noncompliance with Antihypertensive TherapyPharmacoEconomics, 1996
- Clinicians and patients with hypertension: Unsettled issues about complianceAmerican Heart Journal, 1995
- Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertensionThe American Journal of Cardiology, 1995
- Prevalence of Hypertension in the US Adult PopulationHypertension, 1995
- The Cost Effectiveness of Hypertension Treatment in SwedenPharmacoEconomics, 1995
- Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research GroupJAMA, 1991
- The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: A review of randomized controlled trialsProgress in Cardiovascular Diseases, 1986
- MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.BMJ, 1985